Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367651 | 0.86 | ALDH1A1 (0.55) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL15924512 | 0.85 | CYP19A1 (0.56) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL795210 | 0.84 | HPGD (0.68) | HPGDSMN1; SMN2KLKB1CYP19A1HTT | |
| SCHEMBL2367593 | 0.84 | HPGD (0.53) | HPGDLMNASMN1; SMN2P2RY14NPC1 | |
| SCHEMBL2368342 | 0.83 | POLB (0.53) | ALDH1A1HPGDSMN1; SMN2P2RY14PTGER4 | |
| SCHEMBL2368399 | 0.83 | PTGER4 (0.52) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL3757295 | 0.82 | NPC1 (0.57) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL2368252 | 0.80 | NPC1 (0.55) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL2367943 | 0.80 | NPC1 (0.55) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL2367822 | 0.80 | NPC1 (0.52) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316041-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2951185-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009060053-A1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316041-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885ALDH1A1 2288/4885HSD17B10 2431/4885 |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885ALDH1A1 2288/4885HSD17B10 2431/4885 |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885ALDH1A1 2288/4885HSD17B10 2431/4885 |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FASN | KDM4E 1105/4885ALDH1A1 633/4885HSD17B10 40/4885 |
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | KDM4E 2822/4885ALDH1A1 635/4885HSD17B10 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.